Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Common Equity data on record, last reported at $167.6 million in Q1 2026.

  • On a quarterly basis, Common Equity rose 95.52% to $167.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $167.6 million, a 95.52% increase, with the full-year FY2025 number at $172.9 million, up 82.26% from a year prior.
  • Common Equity reached $167.6 million in Q1 2026 per IKT's latest filing, down from $172.9 million in the prior quarter.
  • Over the last five years, Common Equity for IKT hit a ceiling of $172.9 million in Q4 2025 and a floor of -$530591.0 in Q3 2024.
  • A 5-year average of $50.9 million and a median of $25.3 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: tumbled 103.53% in 2024, then skyrocketed 13839.08% in 2025.
  • Tracing IKT's Common Equity over 5 years: stood at $21.0 million in 2022, then tumbled by 47.81% to $11.0 million in 2023, then surged by 764.16% to $94.9 million in 2024, then surged by 82.26% to $172.9 million in 2025, then dropped by 3.06% to $167.6 million in 2026.
  • Business Quant data shows Common Equity for IKT at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.